【摘要】 目的:探讨腹腔化疗在Ⅲ、Ⅳ期上皮性卵巢癌术后辅助治疗中的疗效与安全性。方法:选取获得满意肿瘤细胞减灭术的102例Ⅲ、Ⅳ期上皮性卵巢癌患者,随机分为观察组（51例）和对照组（51例）。对照组给予静脉化疗,观察组给予腹腔化疗联合静脉化疗;对比两组近期疗效、血清肿瘤标志物水平、毒副作用及预后。结果:治疗6个周期后,观察组治疗有效率（52.9%）明显高于对照组（33.3%）（P<0.05）;治疗6个周期后,观察组血清CA₁₂₅（34.62±3.07）U/ml、HE₄（107.23±20.76）pmol/L、TPA（53.51±4.02）U/L水平明显低于对照组CA₁₂₅（38.81±3.36）U/ml、HE₄（168.36±31.54）pmol/L、TPA（63.18±4.18）U/L（P<0.05）;化疗6周期后,观察组不同类型毒副反应发生率与对照组比较无统计学差异（P<0.05）;随访2年,观察组中位生存时间（34个月）明显长于对照组（27个月）（P<0.05）。结论:腹腔化疗联合静脉化疗在Ⅲ、Ⅳ期上皮性卵巢癌术后辅助治疗中疗效较单纯静脉化疗更好,可明显降低患者血清标志物水平,且化疗毒副作用无明显增加,延长了患者的中位生存时间。更多还原

【Abstract】 Objective:To investigate the efficacy and safety of intraperitoneal chemotherapy in the adjuvant treatment of stage Ⅲ and Ⅳ epithelial ovarian cancer.Methods:A total of 102 patients with stageⅢandⅣepithelial ovarian cancer who obtained satisfactory tumor cytoreductive surgery were randomly divided into observation group（51 cases）and control group（51 cases）.The control group was given intravenous chemotherapy,and the observation group was given intraperitoneal chemotherapy combined with intravenous chemotherapy.The short-term efficacy,serum marker levels,toxic side effects and prognosis were compared between the two groups.Results:After 6 cycles of treatment,the effective rate of the observation group（52.9%）was significantly higher than that of the control group（33.3%）（P<0.05）.After 6 cycles of treatment,the serum CA₁₂₅[（34.62±3.07）U/ml],HE₄[（107.23±20.76）pmol/L]and TPA [（53.51±4.02）U/L]in the observation group were significantly lower than CA₁₂₅[（38.81±3.36）U/ml],HE₄[（168.36±31.54）pmol/L],and TPA [（63.18±4.18）U/L]in control group（P<0.05）.After 6 cycles of chemotherapy,the incidence rate of different types of toxic side effects in the observation group was not significantly different from that in the control group（P<0.05）.Followed up for 2 years,the median survival time of the observation group（34 months）was significantly longer than that of the control group（27 months）（P<0.05）.Conclusion:Intraperitoneal chemotherapy combined with intravenous chemotherapy is better than intravenous chemotherapy alone in postoperative adjuvant treatment of stageⅢandⅣepithelial ovarian cancer.It can significantly reduce the serum marker levels,and the toxic side effects of chemotherapy are not significantly increased.It can prolong the median survival time of patients.更多还原